Well I guess it (Europroteome) didn't work very well.
Europroteome, AG, a privately owned German company currently in insolvency proceedings.
Cancer Gene Therapy WeekWelcome to NewsRx!
Business Update
Company acquires rights for 16 cancer targets from Europroteome
June 13th, 2005
Genmab, A/S, announced that it has acquired rights to 16 potential targets to treat nonsteroid-dependent cancers of epithelial cell origin, such as gastrointestinal cancers, including colon cancer, from the insolvency administrator of Europroteome, AG, a privately owned German company currently in insolvency proceedings.
Genmab purchased all of Europroteome's rights, including patent applications and know-how, and does not owe anything further to the insolvency estate. There are no milestone or royalty obligations.
Genmab has started generating human antibodies to a unique target highly expressed on colon carcinomas.
"These rights give Genmab...
